Avraham Pharmaceuticals Ltd. Announces Commencement of a Phase 2 Study of Ladostigil for the Treatment of MCI
5/17/2012 9:59:31 AM
YAVNE, Israel--(BUSINESS WIRE)--Avraham Pharmaceuticals Ltd. announced today the commencement of a Phase 2 clinical trial to evaluate the safety and efficacy of ladostigil in patients diagnosed with mild cognitive impairment (MCI). This 36-month, multi-centre, randomized, double-blind, placebo-controlled trial will include at least 200 patients in 16 centers in Europe and Israel.